Gerard Evan

Gerard Evan
Born (1955-08-17) 17 August 1955 [1]
Fields Cancer[2][3][4][5][6][7]
Disease biology
Myc regulator gene[8]
p53 tumour suppressor[9]
Institutions University of Oxford
University of Cambridge
UCSF[1][10]
Cancer Research UK[11]
Ensemble Therapeutics
Alma mater St Peter's College, Oxford
King's College, Cambridge[1]
Thesis Monoclonal antibodies as reagents for the analysis of cell surfaces (1982)
Doctoral students Maria Christophorou[12][13]
Known for Disease Models & Mechanisms
Notable awards Fellow of the Royal Society (2004)
FMedSci (1999)[14]
PhD (1982)
Website
www.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and Sir William Dunn Professor of Biochemistry at the University of Cambridge.[10][15]

Education

Evan was educated at St Peter's College, Oxford and King’s College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies.[1][16]

Research

Evan's does research to the determine the molecular basis of cancer.[13][17][18][19][20][21][22][23]

Career

Prior to Cambridge, Evan was Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco. Evan is also a member of the Advisory Board, of Ensemble Therapeutics Corporation[24][25] and a founding editor of the journal Disease Models & Mechanisms.[6]

References

  1. 1 2 3 4 "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
  2. ↑ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology 29 (19): 5306–5315. doi:10.1128/MCB.01745-08. PMC 2747972. PMID 19635809.
  3. ↑ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development 25 (16): 1746–1757. doi:10.1101/gad.16722111. PMC 3165938. PMID 21852537.
  4. ↑ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell 14 (6): 447–457. doi:10.1016/j.ccr.2008.10.018. PMC 2723751. PMID 19061836.
  5. ↑ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development 25 (9): 907–916. doi:10.1101/gad.2038411. PMC 3084025. PMID 21478273.
  6. 1 2 Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms 1 (2–3): 90–93. doi:10.1242/dmm.001396. PMC 2562192. PMID 19048069.
  7. ↑ Anon (2008). "Making the paper: Gerard Evan". Nature 455 (7213): xiii. doi:10.1038/7213xiiia.
  8. ↑ Evan, G. (2012). "Taking a Back Door to Target Myc". Science 335 (6066): 293–294. doi:10.1126/science.1217819. PMID 22267799.
  9. ↑ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer 9 (11): 821–829. doi:10.1038/nrc2728. PMID 19776747.
  10. 1 2 "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 2013-06-17.
  11. ↑ "Gerard Evan : Cancer Research UK". Archived from the original on 2013-06-17.
  12. ↑ Christophorou, Maria (2005). Temporal dissection of p53 function in vivo and in vitro (PhD thesis). University of California, San Francisco.
  13. 1 2 Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature 443 (7108): 214–217. doi:10.1038/nature05077. PMID 16957739.
  14. ↑ http://www.acmedsci.ac.uk/p59fid5303.html
  15. ↑ List of publications from Microsoft Academic Search
  16. ↑ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
  17. ↑ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature 468 (7323): 567–571. doi:10.1038/nature09526. PMC 3011233. PMID 21107427.
  18. ↑ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature 455 (7213): 679–683. doi:10.1038/nature07260. PMID 18716624.
  19. ↑ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature 411 (6835): 342–348. doi:10.1038/35077213. PMID 11357141.
  20. ↑ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science 278 (5341): 1305–1309. doi:10.1126/science.278.5341.1305. PMID 9360929.
  21. ↑ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature 374 (6524): 733–736. doi:10.1038/374733a0. PMID 7715730. horizontal tab character in |first7= at position 5 (help); horizontal tab character in |first6= at position 5 (help); horizontal tab character in |first2= at position 5 (help); horizontal tab character in |first5= at position 5 (help)
  22. ↑ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature 359 (6395): 554–556. doi:10.1038/359554a0. PMID 1406976.
  23. ↑ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature 359 (6394): 423–426. doi:10.1038/359423a0. PMID 1406955.
  24. ↑ http://investing.businessweek.com/research/stocks/private/person.asp?personId=38914899
  25. ↑ http://www.ensembletx.com/about/sab.html

External links

Academic offices
Preceded by
Tom Blundell		 Sir William Dunn Professor of Biochemistry at the University of Cambridge
2009–present 		Incumbent
This article is issued from Wikipedia - version of the Saturday, September 05, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.